|
|
Post by mytakeonit on Aug 2, 2020 15:07:41 GMT -5
Well finally someone understands.
And to all those buying gold ... I have a ground safe that you can store it in. Just send it to me and I'll take care of it for you. I'll even pay 10% interest while holding it in safe keeping.
But, that's mytakeonit
|
|
|
|
Post by falconquest on Aug 2, 2020 16:00:29 GMT -5
I have always said that the share price will not appreciate until Mannkind has proven it can sell Afrezza. Keeping costs under control and signing the deal with UTHR are good but Castagna wss supposed to be the marketing guy that could increase Afrezza sales. So far he has failed.
|
|
|
|
Post by awesomo on Aug 2, 2020 16:53:37 GMT -5
You know you’re reaching when a good part of your defense for someone is listing out their failures and claiming their strong suit is “embracing failure”.
That only works if eventually someone gets it, but what’s Mike’s plan for Afrezza at this point? “Rest and grow”?
He’s has three years, and scripts have been stuck in the mud for at least half of his tenure, so don’t blame COVID for it. He’s Also lost a good number of executives under his tenure, including the prized Kendall.
|
|
|
|
Post by babaoriley on Aug 2, 2020 16:54:25 GMT -5
Hi, CCI, I always respect your posts! A fine effort on this last post. Without Covid, I’m confident we would be in the high 800’s in scripts. LOL. Rotten luck. I’m no Mike fan, but it’s not clear to me that anyone MNKD could reasonably hope to take his place would be any better. I completely agree Bob. About the scripts and the Covid. But I want to ask you central...... Are you going to go on record with this statement....,” Mike has the company in a place where it can survive for a long time without diluting the heck out of the shareholders.” When Bill and I went to Headquarters at Westlake it was a very sad experience..it was clear they had tried everything but that they were still swimming up hill, but tired. There’s a better way to market this drug.. at least a different way should be acknowledged. We had to prove that and we have...don’t assume there’s too much animosity:-) We all want the same thing, multiple ideas should be explored. If you wanna know how the animosity started read Steve’s posts about the overseas deals..if you want to know where things stand now read Bill’s letter. “Swimming uphill” - Sports, now you know why MC is known as “The Salmon” among his peers. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 2, 2020 17:06:53 GMT -5
I have always said that the share price will not appreciate until Mannkind has proven it can sell Afrezza. Keeping costs under control and signing the deal with UTHR are good but Castagna wss supposed to be the marketing guy that could increase Afrezza sales. So far he has failed. Afrezza sales are GROWING 55% YOY. What insulin maker is growing sales 55% a year? We all know how difficult it has been for MNKD. If you want to blame someone blame AL MANN (May he RIP). He had 2 CRLs and decided to take the weakest approach for approval. Now MNKD is suffering from that decision. Any CEO coming in would have had a tough time. You guys want to bitch about the negative. Why don't you talk about the TURNAROUND Mike has completed. |
|
|
|
Post by uvula on Aug 2, 2020 19:01:25 GMT -5
My guess is Martine pursued mnkd and Mike had very little to do with the uthc deal. She needed technosphere and got it done.
|
|
|
|
Post by sayhey24 on Aug 2, 2020 19:05:42 GMT -5
I don't know about a turnaround but what I can say is on Tuesday August 4th MNKD turns the page with our new CMO. Maybe he has a few ideas like leveraging the VDex model along with a CGM and connected care partnership.
700+ scripts per week with what should be the greatest selling drug of all time just doesn't seem to good to me.
Mike tries and tries but it seems like most of the time he is in quick sand. Karen Bass is not Westlake's congressman but she is not far away. Here she is going to Cuba in search of a cure for foot ulcers for diabetics while Mike sits on the one thing which can get these T2's sugars under control so they don't have the ulcer issue. Maybe Galindo can give her a call and make her a hero.
|
|
|
|
Post by sportsrancho on Aug 2, 2020 19:15:34 GMT -5
Bill has expressed this to me in the past ....”Sometimes it’s a little hard to believe an outsider could do a better job than insiders. And most times that’s true. It’s easy to criticize but in rare cases (this being one) outsides have a better perspective. Doesn’t mean the outsider is smarter just has A different experience that makes him able to see situations differently.”
Vdex has had a different experience with Afrezza than Mannkind has.
|
|
|
|
Post by falconquest on Aug 2, 2020 19:27:51 GMT -5
I have always said that the share price will not appreciate until Mannkind has proven it can sell Afrezza. Keeping costs under control and signing the deal with UTHR are good but Castagna wss supposed to be the marketing guy that could increase Afrezza sales. So far he has failed. Afrezza sales are GROWING 55% YOY. What insulin maker is growing sales 55% a year? We all know how difficult it has been for MNKD. If you want to blame someone blame AL MANN (May he RIP). He had 2 CRLs and decided to take the weakest approach for approval. Now MNKD is suffering from that decision. Any CEO coming in would have had a tough time. You guys want to bitch about the negative. Why don't you talk about the TURNAROUND Mike has completed. You seem to be becoming the minority in sentiment here Casper. 55% year over year sounds good until you look at the actual numbers. 55% of a small number is still a small number. As I said, it sounds good but you cannot legitimately compare Mannkind to the major players in the diabetes market. "The weakest approach" as you call it, was a point where the FDA had Al Mann backed into a corner. In my opinion he took whatever course of action he could to get it approved and then he could go on to prove Afrezza in the end. So blaming the current CEO's lack of success on Al Mann is near blasphemy here. Care to try again? Oh, and maybe you can elucidate us with this big turn around you mention. It sure isn't reflected in the share price! |
|
|
|
Post by olebob1 on Aug 2, 2020 19:29:13 GMT -5
I don't know about a turnaround but what I can say is on Tuesday August 4th MNKD turns the page with our new CMO. Maybe he has a few ideas like leveraging the VDex model along with a CGM and connected care partnership. 700+ scripts per week with what should be the greatest selling drug of all time just doesn't seem to good to me. Mike tries and tries but it seems like most of the time he is in quick sand. Karen Bass is not Westlake's congressman but she is not far away. Here she is going to Cuba in search of a cure for foot ulcers for diabetics while Mike sits on the one thing which can get these T2's sugars under control so they don't have the ulcer issue. Maybe Galindo can give her a call and make her a hero. Thinking out side of the Black Box! Why not? Works for me SayHey24. |
|
|
|
Post by mytakeonit on Aug 2, 2020 19:53:15 GMT -5
Further outside the Black Box is Wednesday August 5th and conference call day. Should be enlightening to say the least. And it'll help me realize why I loaded up all this stock.
But, that's mytakeonit
|
|
|
|
Post by awesomo on Aug 2, 2020 21:20:26 GMT -5
Further outside the Black Box is Wednesday August 5th and conference call day. Should be enlightening to say the least. And it'll help me realize why I loaded up all this stock. But, that's mytakeonit Maybe one of these days you’ll be right about some enlightening revelation during the conference call, until then, expect more of the same. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 2, 2020 21:23:05 GMT -5
I don't know about a turnaround but what I can say is on Tuesday August 4th MNKD turns the page with our new CMO. Maybe he has a few ideas like leveraging the VDex model along with a CGM and connected care partnership. 700+ scripts per week with what should be the greatest selling drug of all time just doesn't seem to good to me. Mike tries and tries but it seems like most of the time he is in quick sand. Karen Bass is not Westlake's congressman but she is not far away. Here she is going to Cuba in search of a cure for foot ulcers for diabetics while Mike sits on the one thing which can get these T2's sugars under control so they don't have the ulcer issue. Maybe Galindo can give her a call and make her a hero. I think you meant to say CCO not CMO. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 2, 2020 21:25:12 GMT -5
Afrezza sales are GROWING 55% YOY. What insulin maker is growing sales 55% a year? We all know how difficult it has been for MNKD. If you want to blame someone blame AL MANN (May he RIP). He had 2 CRLs and decided to take the weakest approach for approval. Now MNKD is suffering from that decision. Any CEO coming in would have had a tough time. You guys want to bitch about the negative. Why don't you talk about the TURNAROUND Mike has completed. You seem to be becoming the minority in sentiment here Casper. 55% year over year sounds good until you look at the actual numbers. 55% of a small number is still a small number. As I said, it sounds good but you cannot legitimately compare Mannkind to the major players in the diabetes market. "The weakest approach" as you call it, was a point where the FDA had Al Mann backed into a corner. In my opinion he took whatever course of action he could to get it approved and then he could go on to prove Afrezza in the end. So blaming the current CEO's lack of success on Al Mann is near blasphemy here. Care to try again? Oh, and maybe you can elucidate us with this big turn around you mention. It sure isn't reflected in the share price! It's not even worth commenting. Good luck to all..... |
|
|
|
Post by Chris-C on Aug 2, 2020 21:31:53 GMT -5
Bill has expressed this to me in the past ....”Sometimes it’s a little hard to believe an outsider could do a better job than insiders. And most times that’s true. It’s easy to criticize but in rare cases (this being one) outsides have a better perspective. Doesn’t mean the outsider is smarter just has A different experience that makes him able to see situations differently.” Vdex has had a different experience with Afrezza than Mannkind has. I can see merit in most all of the posts in this thread; which ultimately has accomplished very little except to characterize the various camps on this board. Unless I missed it, what has not been said is this: It is undeniable that the accountability for MNKD rests with the board of directors. At the moment, they seem to be satisfied with Mr. Castagna as far as we know, but they too find themselves between a rock and a hard place. Is there a better CEO for the company out there to be recruited? Perhaps, but replacing a CEO can be costly in more ways than one. There are severance payments, and there are opportunity costs associated with the likely recasting of the executive team, confusion and defection during a new executive's learning curve, and the inevitable turnover that comes with any change in a CEO. Clearly MNKD's governing board knows this calculus more than anyone posting here. To expect much of an increase in script numbers under the current limitations of the pandemic seems unrealistic to me. Personally, I'd love it if MNKD simply sold Afrezza to a company with the skill and personnel to drive higher sales and benefit PWDs. But a sale is probably unlikely because the blockbuster status many dreamed would happen seems unrealistic now. A new pharma must contend with the same headwinds that Mannkind is now facing. They do not magically disappear with a new executive. Perhaps Al Mann himself was unwilling to recognize the obstacles; which were clearly made more difficult at FDA approval, and which came much later than expected and at much greater expense to the company than expected. The board is responsible for finding and hiring CEOs. Their track record so far has been lackluster, IMO. Sure, Castagna has not succeeded in moving the script needle much for Afrezza, but neither did the others, and some squandered precious opportunity and were not tuned in enough to imagine that SANOFI might pull the plug. I would assert that, ultimately, insurance companies, corporate medicine, and resistance to change killed Afrezza's chances, not Michael Castagna. In my book, the brightest future lies with licensing technosphere; which after all, is the magic underlying Afrezza. Chris C |
|
